Sirtex Medical Inc.
Sirtex delivers oncology treatments using small particle technology to improve outcomes for patients with cancer. SIR-Spheres® Y-90 resin microspheres target liver tumors with radiation via the hepatic artery during minimally invasive Selective Internal Radiation Therapy (SIRT). SIRFLOX Study data showed a 7.9-month improvement in Progression-Free Survival in the liver for patients with unresectable mCRC treated 1st-line with SIR-Spheres Y-90 resin microspheres plus standard chemotherapy. This opens new treatment options for patients whose tumors can't be resected. Visit www.sirtex.com/SIRFLOX